ADX-102 Ophthalmic Solution (0.5%) FDA decision

The FDA issued a complete response letter for ADX-102 Ophthalmic Solution (0.5%) / Reproxalap on 16 Mar 2026.

FDA decision
16 Mar 2026

Drug identity checked against registry records

Also recorded as Reproxalap

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
A Randomized, Double Masked, Clinical Study of Subjects With Dry Eye SyndromeNCT03162783ALDXPhase 2Completed2017-07-06Actual
SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis.NCT03131154ALDXPhase 3Completed2019-04-19Actual

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2026-03-16DayADX-102 Ophthalmic Solution (0.5%)Aldeyra Therapeutics, Inc. · ALDXFDA complete response letterComplete response letterNot specifiedOpen original source
Read source excerpt

{"application_number": ["NDA 216442"], "letter_date": "03/16/2026", "letter_type": "COMPLETE RESPONSE", "company_name": "Aldeyra Therapeutics, Inc.", "file_name": "CRL_NDA216442_20260316.pdf"}

First seen: 26 Sep 2026 · Evidence last checked: 26 Sep 2026